|
Nov 29, 2021
|
Sesen Bio Strengthens Medical Team
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 29, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the strengthening of its medical team with the hiring of Dominika Kowalski as
|
|
Nov 23, 2021
|
Sesen Bio Director Jane Pritchett Henderson Transitions to CEO Advisor Role
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 23, 2021-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Jane Pritchett Henderson , previously a member of Sesen Bio’s Board of
|
|
Nov 8, 2021
|
Sesen Bio Reports Third Quarter 2021 Financial Results and Business Update
Participated in productive CMC Type A Meeting with the FDA Maintained strong balance sheet with $175M in cash and cash equivalents as of September 30, 2021 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 8, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein
|
|
Nov 1, 2021
|
Sesen Bio Announces Productive CMC Type A Meeting with the FDA
Vicineum™ manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 1, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of
|
|
Oct 12, 2021
|
Sesen Bio Expands CMC and Clinical Teams
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 12, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the expansion of its chemistry, manufacturing, and control (CMC) and clinical
|
|
Aug 13, 2021
|
Sesen Bio Receives Complete Response Letter from FDA for Vicineum™ (oportuzumab monatox-qqrs)
Company to host conference call on Monday, August 16 at 8:00 a.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 13, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that it
|
|
Aug 11, 2021
|
Sesen Bio Strengthens Executive Leadership Team as the Company Approaches the Potential Approval and Commercial Launch of Vicineum™
John Knighton to join Sesen Bio as Vice President and Chief Compliance Officer The Company believes it remains on track for an FDA decision on its BLA for Vicineum by August 18, 2021 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 11, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company
|
|
Aug 9, 2021
|
Sesen Bio Reports Second Quarter 2021 Financial Results and Significant Global Progress for Vicineum™
The Company believes it remains on track for an FDA decision on its BLA for Vicineum by August 18, 2021 The Company also believes it remains on track for potential approval in Europe and key markets in MENA in 2022 Strengthened balance sheet with $151M in cash and cash equivalents as of June 30,
|
|
Aug 5, 2021
|
Sesen Bio Announces Partnership with Eczacibasi Pharmaceuticals Marketing (EIP) for the Commercialization of Vicineum™ in Turkey
Sesen Bio to receive $1.5 million upfront and is eligible for additional regulatory and commercial milestone payments Sesen Bio is entitled to receive a 30% royalty on net sales in Turkey CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company
|
|
Aug 2, 2021
|
Sesen Bio Strengthens Leadership Team as the Company Approaches the Potential Approval and Launch of Vicineum™
Company announces hiring of Amy Ponpipom as Vice President, Assistant General Counsel CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 2, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today
|
